Effect of enteral formula enriched with omega-3 fatty acid to prevention of weight reduction in patients with Parkinson's Disease
- Conditions
- Parkinson's Disease
- Registration Number
- JPRN-UMIN000008057
- Lead Sponsor
- St. Mariannna University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Not provided
1. Patients with parkinsonian syndrome 2. Patients have participated in the other studies or clinical trials of enteral nutrition formula. 3. Patients who have received surgical treatment such as stereotactic neurosurgery within 6 months. 4. Patients with psychological symptom such as severe confusion, hallucination, delusion and abnormal behavior. 5. Patients with cognitive dysfunction (MMSE score is no more than 21) 6. Patients with a history of drug allergy (Including any ingredient of study drug) 7. Patients who have administrated other study drugs and drug of post-marketing clinical trial within 3 months before observation period and have not completed other studies at the time of informed consent 8. Patients judged to be inappropriate for the study by the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Body weight reduction rate ,amount of PD clinical evaluation scale score change (Total score by each part of UPDRS )
- Secondary Outcome Measures
Name Time Method Change rate of albumin, prealbumin, acyl-ghrelin, desacyle-ghrelin, leptin